Halovate CR 0.05% of 30gm

Halovate CR 0.05% is contraindicated in patients with a history of hypersensitivity to Halobetasol propionate, any of the components of this formulation, or other corticosteroids.

The topical medicine should not be used in patients with viral diseases of the skin, including herpes simplex, varicella, and vaccinia. They are also contraindicated in untreated bacterial and fungal infections involving the skin. There are no clinical trials of Topical Halobetasol in pregnant women. Therefore, topical medicine should be used during pregnancy only if the potential benefit justifies the risk to the fetus. The cream should not be used with an occlusive dressing.

The medicine is not for ophthalmic use and should not be used in or near the eyes. If irritation develops, Halovate cream should be discontinued, and appropriate treatment should be introduced. If concomitant skin infections develop, an appropriate antibacterial or antifungal agent should be used. If an improvement does not occur promptly, corticosteroid cream should be discontinued until the infection has been adequately controlled.  

The most frequent side effects reported with topical corticosteroids include stinging, burning, or itching. Less frequently reported side effects were dry skin rash, erythema, and skin atrophy. Most side effects do not require medical attention and resolve as your body adjusts to the medicine.   

Patients using Halovate CR are to be used as directed by the dermatologist. Avoid contact with eyes. The topical medicine should not be used for any disorder other than that for which it was recommended. The treated skin area should not be bandaged, covered, or wrapped to be occlusive unless directed by the dermatologist. Patients should inform their dermatologists of any signs of adverse reactions. Apply a thin layer of cream to the affected skin once or twice a day and rub it gently and completely.

Treatment beyond two consecutive weeks is not recommended. Use in children under twelve years of age is not suggested. As with another active corticosteroid, therapy should be discontinued when control has been attained. The diagnosis may be reassessed if no improvement is observed within two weeks. The topical medicine should not be used with occlusive dressings.